This press release was jointly issued by Amgen, NSG BioLabs and Singzyme.

 

Singzyme, a Singapore-based biotech startup pioneering next-generation bioconjugation solutions, has been named the winner of the 2025 Golden Ticket Programme in Singapore. The award is part of a joint programme by Amgen, a U.S.-based leader in biologic medicines and NSG BioLabs, Singapore's leading provider of biotechnology co-working laboratories and offices.

Now in its fourth year, the Golden Ticket Programme supports promising biotech startups by providing infrastructure, mentorship, and resources to advance scientific progress and talent development in accelerating the development of new therapies. As this year’s awardee, Singzyme will receive a one-year residency at NSG BioLabs, along with access to certified BSL-2 lab facilities and networking opportunities through Amgen’s community of scientific and business leaders.

Singzyme was selected from a competitive pool of six finalists following an interactive pitch session reviewed by Amgen’s internal scientific committee. The startup stood out for its proprietary Peptide Asparaginyl Ligase (PAL) platform, a novel site-specific conjugation technology that addresses key challenges in the manufacturing of antibody-drug conjugates (ADCs) and other complex biologics. The platform holds strong potential for enabling safer, more precise, and efficient production of next-generation targeted therapies.

Singzyme joins a growing list of previous Golden Ticket recipients in Singapore, including Albatroz Therapeutics, VerImmune, and PairX Bio. These companies have leveraged the programme’s access and visibility to further their research, raise funding, and expand partnerships. Albatroz secured US$3 million in seed funding to advance its drug development programmes, while VerImmune’s recent closure of the first half of its Pre-Series A round reflects strong confidence in its platform and trajectory.

Unlocking Biotech Growth Through Cross-Sector Collaboration

Accelerating biotech startups takes more than breakthrough science, it requires the right mix of mentorship, infrastructure, and collaboration. This was the key message shared at a panel discussion held at the award ceremony, titled “Powering Biotech Breakthroughs: Scaling Science Through Cross-Sector Collaboration.” Speakers from Amgen, ClavystBio, and the Singapore Economic Development Board (EDB) discussed how cross-sector collaboration is helping startups progress from scientific concepts to real-world applications. The discussion emphasized the importance of a dynamic ecosystem – one that offers shared infrastructure, strong talent pipelines, and access to mentorship – to support biotech ventures and enable researchers and entrepreneurs to grow and scale globally.